NeuroElement Brain Supplement
NEUROELEMENT
The Problem Nobody Talks About
The brain runs on chemical elements — not brand names. There are exactly 14 elements that the human brain requires to synthesize neurotransmitters, maintain neural structures, regulate enzymes, and protect against oxidative damage. Every brain disease — from Alzheimer's to ADHD to epilepsy — can be traced back to disruptions in the pathways those elements power.
But nobody had ever asked the real question:
"What is the minimum set of compounds needed to deliver the maximum number of brain-essential elements, through the blood-brain barrier, in bioavailable form?"
Until now.
A 20-Year Discovery
This wasn't a weekend project. This was a near-20-year investigation into the elemental architecture of the human brain.
Construction of comprehensive databases cataloguing 54 brain diseases, 65 neurotransmitters, and their chemical element dependencies. Every neurotransmitter was broken down to its atomic formula. Every disease was mapped to the biochemical mechanisms it disrupts.
A novel classification emerged: brain diseases split cleanly into two molecular-weight groups — neurological (HN, MW 15.024) and psychiatric (HC, MW 13.019). This binary pattern had never been identified in the literature. It changed everything about how the formulation was designed.
A computational method was developed to test every possible combination of brain elements against 40 neurobiochemical mechanisms and 18 disease categories. Each combination was scored on mechanism coverage (MCS) and disease coverage (DCS). The algorithm identified the optimal set: 10 elements, deliverable through 7 precision compounds.
Three critical "assembly line" discoveries: neurotransmitter synthesis pathways that require multiple elements in strict sequence. A deficiency at any point in the chain breaks the entire downstream pathway. The formulation was designed to supply every link in every chain.
Seven compounds were selected — each chosen for demonstrated blood-brain barrier crossing, bioavailability, and element delivery specificity. A divided dosing protocol was designed to prevent inter-element competition and align each compound's pharmacology with the body's circadian neurochemistry.
U.S. Application No. 19/555,525. A nonprovisional utility patent with 24 claims covering the composition of matter, computational design method, formulation process, and method of treatment. Filed at the United States Patent and Trademark Office.
Coverage That No Competitor Can Match
Other supplements target one pathway. Maybe two. This formulation was algorithmically optimized to cover the maximum possible range of brain biochemistry with the minimum number of compounds.
Mechanism Coverage
34 of 40 known brain biochemical mechanisms addressed by 7 compounds
Disease Coverage
16 of 18 major brain disease categories addressed across all evolutionary tiers
Element Delivery
10 of 14 brain-essential elements delivered (4 remaining obtained from normal diet)
What Makes This Different From Everything Else
Element-Level Design
Not designed at the ingredient level. Designed at the chemical element level — the same atoms your brain uses to build neurotransmitters. Then the optimal delivery compounds were selected.
Computational Optimization
Every possible element combination was scored against 40 brain mechanisms and 18 disease categories. The algorithm found the maximum-coverage set. No guesswork. Pure math.
Blood-Brain Barrier Crossing
Every compound was selected specifically for demonstrated ability to cross the blood-brain barrier. Other supplements use cheap forms that never reach the brain.
Patent-Protected
U.S. Patent Application 19/555,525 with 24 claims covering the composition, manufacturing method, treatment method, and computational design method. This formulation is legally protected.
Circadian-Aligned Dosing
A divided AM/PM protocol prevents element competition, aligns calming compounds with sleep, and ensures 24-hour continuous coverage for the two most critical brain elements.
20 Years of Research
This formulation is the product of nearly two decades of investigation into brain chemistry, neurotransmitter synthesis, and disease mechanisms. You can't speed-run 20 years.
A Discovery That Rewrites Brain Medicine History
During the research, a convergence was discovered that had never been documented in the scientific literature:
Three completely independent timelines — evolutionary brain age, historical drug discovery dates, and pharmacokinetic onset speed — all produce the exact same ordering of brain disease categories:
PAIN → CONTROL → DELUSIONAL → MEMORY
Older brain structures respond to faster drugs that were discovered earlier in history. The brain was built bottom-up, and our pharmaceutical timeline unconsciously followed the same blueprint.
The formulation targets all four evolutionary categories simultaneously — the only composition designed to operate across the complete evolutionary architecture of the human brain.
Market Position & Valuation
Intellectual Property Valuation
Based on comparable transactions (Onnit/Unilever $250-400M, Prevagen $165M revenue, industry 10.7x EBITDA multiples), patent protection, computational method IP, and 20 years of irreproducible research:
Full technology transfer including patent application, complete specification, computational databases, formulation recipe, manufacturing SOPs, and 9 patent drawings (SVG). No intellectual property retained by seller — complete transfer.
What's Included in the Technology Transfer
| Deliverable | Description | Format |
|---|---|---|
| U.S. Patent Application | Complete nonprovisional utility patent (19/555,525) with 24 claims, 68 specification paragraphs | DOCX, Filed |
| Patent Drawings | 9 professional vector patent figures — composition diagram, mechanism chart, disease matrix, flowcharts, assembly lines, dosing schedule | SVG |
| Formulation Recipe | Complete ingredient list with exact weights, excipients, capsule specifications for AM and PM doses | Within patent spec |
| Manufacturing Method | Step-by-step mixing method with geometric dilution, blending times, light protection, QC specifications | Within patent spec |
| Computational Databases | JSON databases: 54 diseases, 65 neurotransmitters, 40 mechanisms, 20 elements, cross-reference mappings | JSON |
| Research Software | Database tools, report generators, timeline systems, analysis scripts | Python |
| Research Documentation | Evolutionary medicine timeline, disease cross-reference, compound analysis report, IP strategy | MD/TXT |
| Filing Documentation | USPTO filing receipt, confirmation #9226, patent center #74702743, complete filing checklist | PDF/TXT |
Competitive Landscape
| Feature | NeuroElement | Qualia Mind ($159) | Alpha Brain ($80) | Mind Lab Pro ($69) | Prevagen ($90) |
|---|---|---|---|---|---|
| Patent Protected | YES - Full formulation | NO | NO | NO | PARTIAL - Single ingredient |
| Mechanism Coverage | YES - 85% (quantified) | Not quantified | Not quantified | Not quantified | Not quantified |
| Disease Coverage | YES - 89% (quantified) | Not quantified | Not quantified | Not quantified | Not quantified |
| Design Method | YES - Computational algorithm | Expert formulation | Expert formulation | Expert formulation | Single ingredient |
| BBB Crossing Verified | YES - All 7 compounds | Partial | Partial | Partial | Questionable |
| Element-Level Design | YES - 10 of 14 elements | NO | NO | NO | NO |
| Divided Dosing Protocol | YES - Circadian-aligned AM/PM | NO - Single dose | NO - Single dose | NO - Single dose | NO - Single dose |
| Research Pedigree | YES - ~20 years | ~5 years | ~10 years | ~7 years | ~15 years |
Acquire This Technology
Twenty years of brain chemistry research. Patent-pending. Ready for manufacturing. Ready for market.
MAKE AN OFFERContact: crioneaka@outlook.com • Reference: US App 19/555,525
All content, research, databases, formulations, computational methods, and patent claims described herein are the exclusive intellectual property of Christopher Gabriel Brown.
U.S. Patent Application No. 19/555,525 • Filed March 3, 2026 • USPTO Confirmation #9226
Base, No IP unless separately agreed in writing. © 2026 Christopher Gabriel Brown. All rights reserved.
